Page 60 - 75_01
P. 60
CABRERA FIGUEROA, S. & COL. AN. R. ACAD. NAC. FARM.
9. Markowitz, M. (2000) Resistance, fitness, adherence, and potency: mapping the
paths to virologic failure. JAMA. 283: 250-251.
10. Austin, D., Ferguson, N., Fraser, C. & Roms, K. (1999) Understanding antiretro-
viral treatment failure: the role of pharmacokinetic/dynamycs and patient non-
compliance in the emergence of resistance. 7th European Conference on Clinical
Aspects and treatment of HIV-infection. Lisboa. October 1999 [abstract 212].
11. Paris, D., Ledergerber, B., Weber, R., Jost, J., Flepp, M., Opravil, M., Ruef, C. &
Zimmerli, S. (1999) Incidence and predictors of virologic failure of antiretrovi-
ral triple-drug therapy in a community-based cohort. AIDS Res. Hum.
Retroviruses. 15: 1631-1638.
12. Watson, D.C. & Farley, J.J. (1999) Efficacy of and adherence to highly active an-
tiretroviral therapy in children infected with human immunodeficiency virus type
1. Pediatr. Infect. Dis. J. 18: 682-689.
13. San Francisco AIDS Foundation. La terapia de salvamento. Disponible en:
http://www.sfaf.org/tratamiento/betaespanol/s52/s52_salvamento.pdf. Revisado: Enero 2008.
14. HIV Pharmacology USA. Updated Guidelines 2006. HIVPharmacology.com
Avaliable from: http://www.hivpharmacology.com. Cited on July 2008.
15. Aymard, G.; Legrand, M., Trichereau, N. & Diquet, B. (2000) Determination of twel-
ve antiretroviral agents in human plasma sample using reversed-phase high-perfor-
mance liquid chromatography. J. Chromatogr. B. Biomed. Sci. Appl. 744: 227-240.
16. Colombo, S., Guignard, N., Marzolini, C., Telenti, A., Biollaz, J. & Decosterd, L.A.
(2004) Determination of the new HIV-protease inhibitor atazanavir by liquid
chromatography after solid-phase extraction. J. Chromatogr. B. Analyt. Technol.
Biomed. Life Sci. 810: 25-34.
17. Department of Health and Human Services. Guidance for Industry: Bioanalytical
Method Validation. Food and Drug Administration (U.S.) Available from:
http://www.fda.gov/cder/guidance/4252fnl.pdf. Cited on January 2008.
18. McDougal, J.S., Martin, L.S., Cort, S.P., Mozen, M., Heldebrant, C.M. & Evatt,
B.L. (1985) Thermal inactivation of the acquired immunodeficiency syndrome
virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with
special reference to antihemophilic factor. J. Clin. Invest. 76: 875-877.
19. Abbottbase Pharmacokinetic Systems. (1991) Abbott Laboratories. Diagnostic
Division Abbott Park, Illinois.
20. Leape, L.L., Kabcenell, A. & Berwick, D.M. (1998) Breakthrough Series Guide:
Reducing adverse drug events. Institute for Healthcare Improvement, Boston.
21. Panel de Consenso. (2002) Segundo Consenso de Granada sobre Problemas
Relacionados con Medicamentos. Ars. Pharm. 43: 175-184
22. Marzolini, C., Telenti, A., Decosterd, L.A., Greub, G., Biollaz, J. & Buclin, T. (2001)
Efavirenz plasma levels can predict treatment failure and central nervous system
side effects in HIV-1-infected patients. AIDS. 15: 71-75.
*Información de Contacto:
Dr. Salvador Cabrera Figueroa.
Servicio de Farmacia, Hospital Universitario de Salamanca.
Paseo de San Vicente 58-182. 37007 Salamanca.
Teléfono: 923-291172. FAX: 923-291174.
Email: farpacex@husa.sacyl.es
62
